$COAG

Hemab Therapeutics' Sutacimig Continues to Support Durable Bleed Reduction, Wedbush Says

Hemab Therapeutics' (COAG) sutacimig continues to support clinically meaningful and durable bleed reduction in Glanzmann thrombasthenia, based on the company's phase 2 long-term extension data, Wedbush Securities said in a Tuesday note.Across the efficacy-evaluable population, sutacimig reduced annualized treated bleeding rate by 47% over the combined treatment and extension periods, with benefit observed across dose levels, bleed locations, and bleed etiologies.Additionally, the 47% reduction in annualized treated bleeding rate over the combined treatment and extension periods matched the 47% reduction observed during the initial 12-week treatment period alone, supporting a durable effect over extended dosing, according to the note.The investment firm said that beyond sutacimig, it was encouraged by updates related to HMB-002 in von Willebrand disease and the introduction of HMB-003, reinforcing a "positive view" on the company's bleeding-disorder franchise.Wedbush reiterated its outperform rating with a $55 price target.Price: $39.41, Change: $-0.10, Percent Change: -0.25%

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) fell 1.4%.In corporate news, Conmed (CNMD) shares jumped 9% after Bloomberg Law reported that the company is exploring options including a potential sale amid takeover interest from private equity firms.A federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder. Kenvue shares were down 1.5%.Humana (HUM) shares gained 4.1% after Wells Fargo upgraded the company's stock to overweight from equal-weight and increased the price target to $502 From $227.Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a note. Hemab shares rose 3.3%, and Incyte was down 1.5%.

Sector Update: Healthcare Stocks Higher Monday Afternoon

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index rising 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) fell 1.6%.In corporate news, a federal appeals court on Monday vacated a district court's earlier dismissal of plaintiff claims that they were not warned that prenatal ingestion of Kenvue's (KVUE) Tylenol and its generic equivalents could cause autism spectrum disorder and attention-deficit/hyperactivity disorder. Kenvue shares were down 1.4%.Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a note. Hemab shares gained 6.5%, and Incyte was down 1.8%.Niagen Bioscience (NAGE) has received rare pediatric disease designation from the US Food and Drug Administration for NB4168 in treating ataxia telangiectasia, a multisystem disorder, the company said Monday. Its shares rose 1.6%.

Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says

Hemab Therapeutics' (COAG) HMB-002 is particularly well suited for Type 1 von Willebrand disease patients despite encouraging early data from Incyte's (INCY) latarcibart, Wedbush Securities said in a Monday note.The investment firm said in the research note that HMB-002 is particularly well suited for Type 1 patients, who comprise about 75% of the diagnosed Von Willebrand disease population, because it targets restoration of the underlying von Willebrand factor.The analysts noted that HMB-002 has demonstrated encouraging preliminary clinical efficacy, with eight of nine evaluable patients experiencing no treated bleeding events during the 28 days following a single dose.Multidose Part B data expected in late 2026 or early 2027 should provide the first assessment of whether the early efficacy observations translate into durable bleed reduction with chronic dosing, according to the note.Wedbush reiterated its outperform rating and $55 price target on the stock.Shares of Hemab were up 2% in Monday trading.Price: $38.79, Change: $+0.75, Percent Change: +1.99%

HC Wainwright Initiates Hemab Therapeutics at Buy With $40 Price Target

Wedbush Initiates Hemab Therapeutics at Outperform With $42 Price Target

Jefferies & Co Initiates Coverage on Hemab Therapeutics With Buy Rating, $39 Price Target

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target

Top Midday Gainers

Cue Biopharma (CUE) shares soared 144% a day after the company said it signed a roughly $30 million PIPE financing with certain investors, and also appointed Shao-Lee Lin as president and chief executive.More than 16.3 million shares of the company traded intraday compared with a daily average of about 356,000.Hemab Therapeutics (COAG) said Thursday it priced its initial public offering of 16.8 million shares at $18 per share for gross proceeds of $301.5 million.Shares, which began trading on the Nasdaq Global Select Market on Friday, were up 66% intraday, with a trading volume of 1.87 million.Twilio (TWLO) delivered Q1 results that exceeded expectations, with accelerating momentum across AI-driven use cases and stronger-than-expected business performance, Morgan Stanley said Friday in a report.Shares surged 20%, with intraday trading volume at over 4.44 million from a daily average of roughly 2.44 million.Price: $34.70, Change: $+19.96, Percent Change: +135.41%